10 results match your criteria: "Zigong NO.1 People's Hospital[Affiliation]"
Asian J Surg
November 2024
Department of Traditional Chinese Medicine Department, Zigong NO.1 People's Hospital, Zigong, 643000, China.
Asian J Surg
August 2024
Department of Nursing, Zigong NO.1 People's Hospital, Zigong, 643000, China.
Asian J Surg
October 2023
Department of Traditional Chinese Medicine Department, Zigong NO.1 People's Hospital, Zigong, 643000, China.
Asian J Surg
June 2023
Department of Traditional Chinese Medicine Department, Zigong NO.1 People's Hospital, Zigong, 643000, China. Electronic address:
Asian J Surg
May 2023
Department of Traditional Chinese Medicine Department, Zigong NO.1 People's Hospital, Zigong, 643000, China.
Asian J Surg
April 2023
Department of Neurology, Cangzhou Clinical College of Integrated Traditional Chinese and Western Medicine of Hebei Medical University, Cangzhou, 061000, China.
Asian J Surg
October 2021
Department of Orthopaedics, Neijiang Hospital of Traditional Chinese Medicine, Neijiang, 641000, China.
Oncol Lett
March 2020
Department of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, P.R. China.
Citron kinase (CIT) is a Rho-effector protein kinase that is associated with several types of cancer. However, the role of CIT in prostate cancer (PCa) is unclear. The current study utilized microarray data obtained from The Cancer Genome Atlas, which was analyzed via Biometric Research Program array tools.
View Article and Find Full Text PDFProstate
February 2017
Department of Health Statistics and Information Management, School of Public Health and Management, Chongqing Medical University, Chongqing, China.
Background: Currently, the role of UPR signaling in prostate cancer (PCa) is unclear. To evaluate the relationship between UPR signaling pathway and the prognosis of PCa, we explored the expression of IRE1, PERK, and ATF6 in tissues.
Methods: A total of 160 PCa and 30 benign prostate hyperplasia (BPH) tissues were collected.
Cochrane Database Syst Rev
October 2008
Department of Internal Medicine, Zigong No. 1 People's Hospital, Zigong Renji Medical Centre, No 42, Shang Yi Jing Yi Zhi Lu, Zigong, Sichuan Province, China, 64300.
Background: Dengzhanhua preparations are widely used in China. Many controlled trials have been undertaken to investigate the efficacy of dengzhanhua preparations in the treatment of acute cerebral infarction.
Objectives: To assess whether dengzhanhua preparations are effective and safe at improving outcomes in patients with acute cerebral infarction.